Robert E. Claypoole

CIK: 0002005474

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (10.0%)

Position reduction

Option Exercises (M)3 (30.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BVS

Bioventus Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

BVS
Bioventus Inc.
Mar 13, 2026
Award(A)
Stock Option (Right to Buy)
Direct
309K shares-
BVS
Bioventus Inc.
Mar 13, 2026
Award(A)
Restricted Stock Units
Direct
278K shares-
BVS
Bioventus Inc.
Mar 13, 2026
Exercise(M)
Direct
33.5K shares-
BVS
Bioventus Inc.
Mar 13, 2026
Tax Payment(F)
Direct
14.6K shares at avg. $8.62$125K
BVS
Bioventus Inc.
Jan 9, 2026
Exercise(M)
Direct
93.8K shares-
BVS
Bioventus Inc.
Jan 9, 2026
Tax Payment(F)
Direct
41.7K shares at avg. $8.03$335K
BVS
Bioventus Inc.
Mar 14, 2025
Award(A)
Restricted Stock Units
Direct
134K shares-
BVS
Bioventus Inc.
Mar 14, 2025
Award(A)
Stock Option (Right to Buy)
Direct
153K shares-
BVS
Bioventus Inc.
Jan 13, 2025
Sale(S)
Direct
28.8K shares at avg. $9.10$262K
BVS
Bioventus Inc.
Jan 10, 2025
Exercise(M)
Direct
93.8K shares-

		Type	Shares	Price		Ownership
Mar 13, 2026	BVS Bioventus Inc.	Award(A) Stock Option (Right to Buy)	309,000	-	-	Direct
Mar 13, 2026	BVS Bioventus Inc.	Award(A) Restricted Stock Units	278,000	-	-	Direct
Mar 13, 2026	BVS Bioventus Inc.	Exercise(M)	33,500	-	$0	Direct
Mar 13, 2026	BVS Bioventus Inc.	Tax Payment(F)	14,553	$8.62	$125,447	Direct
Jan 9, 2026	BVS Bioventus Inc.	Exercise(M)	93,750	-	$0	Direct
Jan 9, 2026	BVS Bioventus Inc.	Tax Payment(F)	41,717	$8.03	$334,988	Direct
Mar 14, 2025	BVS Bioventus Inc.	Award(A) Restricted Stock Units	134,000	-	-	Direct
Mar 14, 2025	BVS Bioventus Inc.	Award(A) Stock Option (Right to Buy)	153,000	-	-	Direct
Jan 13, 2025	BVS Bioventus Inc.	Sale(S)	28,786	$9.10	$261,953	Direct
Jan 10, 2025	BVS Bioventus Inc.	Exercise(M)	93,750	-	$0	Direct

1-10 of 10 transactions

About Claypoole Robert E

Claypoole Robert E (SEC CIK 0002005474) files insider reports with the SEC as President and CEO of Bioventus Inc. (BVS).

Signal8 holds 4 ownership filings by Claypoole Robert E, all Form 4s, filed between Jan 13, 2025 and Mar 17, 2026. Those filings report 10 transactions, from Jan 10, 2025 to Mar 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Claypoole Robert E's filings is in DURHAM, NC.

Recent filings by Claypoole Robert E

Mar 13, 2026: Grants or awards of BVS derivative securities (2 lines, Form 4, code A).
Mar 13, 2026: Option exercise of BVS shares (Form 4, code M).
Mar 13, 2026: Tax withholding of BVS shares (Form 4, code F).
Jan 9, 2026: Option exercise of BVS shares (Form 4, code M).
Jan 9, 2026: Tax withholding of BVS shares (Form 4, code F).

Other insiders filing for Bioventus Inc. (BVS)

How to read Form 4 transaction codes